{"public_id":"cl_6880730cb91d99a97f8007a86a03e5fc","status":"active","superseded_by_public_id":null,"corpus_id":205089095,"text":"In 603 patients with estimated glomerular filtration rate of 15.0 to 35.0 ml per minute per 1.73 m2 and mild-to-moderate anemia, participants were randomly assigned to normal-range or subnormal-range target hemoglobin values, with epoetin beta started immediately in the normal-range group or after hemoglobin fell below 10.5 g per deciliter in the subnormal-range group.","confidence":0.98,"paper":{"corpus_id":205089095,"title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","url":"https://sah.borca.ai/papers/205089095"},"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_9b1de4aa510a29d4e9ac5aa0e1cf8c72","name":"epoetin beta","description":"The subcutaneous erythropoietin treatment used to raise hemoglobin levels in the trial groups.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_9b1de4aa510a29d4e9ac5aa0e1cf8c72"},{"public_id":"co_a3010753680409e35d34070d8f39a00c","name":"estimated glomerular filtration rate","description":"A kidney function measure used to define eligibility and track progression in the patient groups.","types":["measurement"],"url":"https://sah.borca.ai/concepts/co_a3010753680409e35d34070d8f39a00c"},{"public_id":"co_f6387de60568eabf307d97f5e9917661","name":"mild-to-moderate anemia","description":"The baseline anemia severity in eligible patients, defined by hemoglobin levels of 11.0 to 12.5 g per deciliter.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_f6387de60568eabf307d97f5e9917661"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_6880730cb91d99a97f8007a86a03e5fc"}